By Dr. Drew Edwards, EdD | April 14, 2026
I've spent thirty years treating people after addiction has already dismantled their careers, their marriages, their health. And in all that time, one question has nagged at me more than any other: why do we wait?
We don't wait for diabetes. A doctor sees elevated fasting glucose and intervenes with diet changes, metformin, monitoring. We don't wait for heart disease. High cholesterol gets flagged at a routine physical, years before the first chest pain. But with addiction? We sit back and watch people spiral until they lose everything, then offer them a 28-day program with a 40-60% relapse rate and call that treatment.
That's changing. And the concept driving the change is one word: preaddiction.
What "preaddiction" actually means
The term comes from Kenneth Blum, PhD, and colleagues, who published a framework connecting Reward Deficiency Syndrome (RDS) to a measurable, genetically identifiable pre-addiction state. Their argument is straightforward: if addiction is a brain disorder rooted in dopamine dysfunction, and if that dysfunction has genetic markers, then we can identify who's at risk before the first drink, the first pill, the first bet.
A 2023 study in Genomics, Proteomics & Divergence analyzed over 88.8 million genome-wide association study (GWAS) samples and identified 18 genes significantly linked to opioid vulnerability, pain processing, and dopaminergic pathways. Eighteen genes. That's not a vague predisposition. That's a biological fingerprint.
At the center of this sits the DRD2 gene, specifically the A1 allele of the dopamine D2 receptor. People carrying this variant produce fewer D2 receptors in the striatum, the brain's reward hub. Fewer receptors means less dopamine signaling. Less dopamine signaling means the brain's baseline state feels restless, unsatisfied, incomplete. These are the people who, as adolescents, reach for substances or behaviors that artificially spike what their neurochemistry can't produce on its own.
RDS is a brain disorder. I've said it a thousand times. Preaddiction is RDS before it has a name on someone's insurance form.
Why conventional treatment misses this entirely
Here's the part that should make you angry. The standard addiction treatment model in the United States does almost nothing to address the neurobiology driving the behavior.
Most programs focus on behavioral modification: group therapy, 12-step facilitation, cognitive behavioral techniques. These have value. I'm not dismissing them. But imagine treating a diabetic with only talk therapy about making better food choices while ignoring their insulin levels. That's what we do with addiction every single day in this country.
The relapse numbers tell the story. NIDA reports 40-60% of people in recovery relapse. In the first year alone, that number climbs to 60-70%. After five years of sustained recovery, risk drops to about 15%, matching the general population. So the question becomes: what are we doing in those first years to protect the neurobiological recovery that's actually happening beneath the surface?
Mostly? Nothing. Most people leave a treatment facility with a list of meetings to attend and a prayer that willpower holds. Their dopamine receptors are still depleted. Their prefrontal cortex is still impaired. Their stress-response system is still dysregulated. And we're surprised when they relapse.
Genetic testing exists. We're just not using it.
The Genetic Addiction Risk Severity (GARS) test was developed specifically to assess dopaminergic vulnerability. It measures polymorphisms across multiple reward genes: DRD2, DRD4, DAT1, COMT, and others. The result is a risk score that tells clinicians whether someone's reward circuitry is genetically compromised before a substance has ever entered their body.
Combined with the Reward Deficiency Syndrome Questionnaire (RDSQ), which captures behavioral and psychological markers, clinicians now have a two-pronged screening tool. Genetics on one side. Phenotype on the other.
Think about what this means for a 16-year-old with a family history of alcoholism. Instead of waiting to see if they develop a problem, we could screen them, identify their neurobiological risk profile, and intervene with targeted nutritional support, behavioral strategies, and monitoring. We could catch the fire before it starts.
What nutrition has to do with it
Dopamine homeostasis doesn't happen in a vacuum. The brain needs raw materials to manufacture and regulate neurotransmitters. When those materials are missing, and they often are in people with genetic reward deficiencies, the brain operates at a deficit.
Amino acids like L-tyrosine and 5-HTP serve as precursor molecules for dopamine and serotonin synthesis, respectively. Without adequate precursors, the brain can't produce the neurotransmitters it needs regardless of how many receptors are available. Action Potential's 5-HTP supplement supports serotonin production, which works in tandem with dopamine to regulate mood and reward processing.
B vitamins, particularly B6, B9, and B12, are cofactors in the enzymatic pathways that convert amino acids into active neurotransmitters. A deficiency in any one of these can bottleneck the entire process. The Complete Multivitamin covers this gap with bioavailable forms of all three.
Neuroprotective compounds like those found in Lion's Mane Mushroom have shown promise in supporting nerve growth factor (NGF) production. For a brain recovering from substance use, or for one genetically predisposed to reward deficiency, protecting existing neural architecture matters.
And for daily cognitive support during recovery or risk management, the Brain Focus Nootropic Formula combines several compounds that support attention, working memory, and executive function, all of which are compromised in people with dopaminergic dysfunction.
The research behind these connections is extensive. We've compiled over 400 peer-reviewed studies on our Evidence page.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
The real question
We screen for prediabetes. We screen for precancerous cells. We screen for cardiovascular risk factors in people who feel perfectly fine. So why aren't we screening for preaddiction in teenagers with family histories, in patients prescribed opioids, in anyone walking into a primary care office?
The tools exist. The science is there. What's missing is the will to shift from reactive treatment to proactive prevention.
If you or someone you know has a family history of addiction, don't wait for the crisis. Start with the biology. Because Addictive Disease doesn't begin the day someone picks up a substance. It begins the day they're born with a brain that was never given what it needed.
Frequently asked questions
What is preaddiction?
Preaddiction is a clinical concept describing a measurable, genetically identifiable state of neurobiological vulnerability to addiction, specifically dopamine dysfunction linked to Reward Deficiency Syndrome, that exists before any substance use begins.
Can a genetic test really predict addiction risk?
The Genetic Addiction Risk Severity (GARS) test measures polymorphisms in reward-related genes like DRD2, DAT1, and COMT. It doesn't predict addiction with certainty, but it identifies heightened neurobiological risk, similar to how cholesterol levels indicate cardiovascular risk.
What is Reward Deficiency Syndrome?
Reward Deficiency Syndrome (RDS) is a condition characterized by reduced dopamine signaling in the brain's reward circuitry. It's linked to genetic variants that produce fewer dopamine receptors, resulting in a baseline state of dissatisfaction that drives compulsive reward-seeking behavior.
How do supplements support dopamine function?
Specific nutrients serve as precursors and cofactors in neurotransmitter production. Amino acids like 5-HTP support serotonin synthesis, B vitamins enable enzymatic conversion pathways, and neuroprotective compounds like lion's mane support nerve growth factor production.
Why do so many people relapse after treatment?
Conventional treatment primarily addresses behavioral patterns without correcting the underlying neurobiological deficits: depleted dopamine receptors, impaired prefrontal function, and dysregulated stress response. These biological vulnerabilities persist long after behavioral treatment ends.
